KROS (Keros Therapeutics) YoY EBITDA Growth: -58.81% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KROS Keros Therapeutics Inc KROS
52 GF Score
Price $11.18
GF Value $10.10
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Keros Therapeutics YoY EBITDA Growth?

Keros Therapeutics KROS -1.33% 52 YoY EBITDA Growth is -58.81% as of Jun. 2026. GuruFocus rates KROS with a GF Score™ of 52/100 and a GF Value™ of $10.10 (Modestly Overvalued). The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Keros Therapeutics's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -58.81%.

Keros Therapeutics's EBITDA per Share for the three months ended in Jun. 2026 was $-1.54.

Keros Therapeutics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Keros Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keros Therapeutics YoY EBITDA Growth Chart

Keros Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial 17.24 -70.60 -25.44 -7.70 132.79

Keros Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.09 76.22 19.05 -134.94 -58.81
KROS
52GF Score
Keros Therapeutics Inc KROS
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Keros Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Keros Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(1.825--5.566)/ | -5.566 |
=132.79 %

Keros Therapeutics's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-1.542--0.971)/ | -0.971 |
=-58.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -58.81% mean?
Keros Therapeutics (KROS) has a YoY EBITDA Growth of -58.81% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Keros Therapeutics and its competitors.
Is Keros Therapeutics' YoY EBITDA Growth too high?
Keros Therapeutics' current YoY EBITDA Growth is -58.81%. Overall, Keros Therapeutics has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' YoY EBITDA Growth compare to VYGR and CHRS?
Keros Therapeutics' YoY EBITDA Growth of -58.81% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Keros Therapeutics and its competitors. Keros Therapeutics's current YoY EBITDA Growth is -58.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Keros Therapeutics (KROS) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.10, compared to a current price of $11.18 — trading 10.7% above its estimated fair value. The current YoY EBITDA Growth is -58.81%. Keros Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current YoY EBITDA Growth is -58.81% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Keros Therapeutics (KROS) Overvalued in 2026?

Based on GuruFocus' analysis, Keros Therapeutics stock appears to be overvalued. The current stock price of $11.18 is trading 10.7% above its estimated GF Value™ of $10.10. GuruFocus considers Keros Therapeutics to be Modestly Overvalued.

Key valuation signals for KROS:

  • YoY EBITDA Growth: -58.81%
  • GF Value™: $10.10 vs. price of $11.18 (10.7% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the KROS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Keros Therapeutics Business Description

Address 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
52GF Score

Get the complete analysis for KROS

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.18
Price
$10.10
GF Value